BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 16, 2025
Home » Newsletters » BioWorld

BioWorld

Nov. 2, 2012

View Archived Issues

Shotgun Partnering Approach for Vertex in All-Oral HCV Race

Moving aggressively to gain ground in the race for an all-oral hepatitis C virus (HCV) regimen, Vertex Pharmaceuticals Inc., of Cambridge, Mass., has put forward its nucleotide analogue HCV polymerase inhibitor, VX-135, in two collaborative, proof-of-concept Phase II trials with two different pharma partners. Read More

Top Colorectal Cancer Risk SNP Works Through Its Effect on Myc

The single nucleotide polymorphism, or SNP, that accounts for more cases of inherited cancer than any other is rs6983267. That gene, said Jussi Taipale, of the Swedish Karolinska Institutet, increases the risk of developing colorectal cancer by about 20 percent. Read More

Cornerstone Mulls Next Steps for Lixivaptan After CRL

With government offices still hampered by the cleanup from Hurricane Sandy, the FDA was several days late responding to Cornerstone Therapeutics Inc.'s new drug application for lixivaptan. The decision, reported Thursday, was no shocker. Read More

Other News To Note

• Cardiome Pharma Corp., of Vancouver, British Columbia, said Nasdaq granted the firm's request for an additional 180 days to regain compliance with the $1 minimum bid price requirement. Read More

Earnings Roundup

• AMAG Pharmaceuticals Inc., of Lexington, Mass., reported total revenues for the third quarter of $17.7 million, falling short of analyst estimates of $20.4 million. Revenue included $16.2 million in net U.S. sales for iron deficiency product Feraheme (fermuoxytol), which increased over the second quarter of 2012 due to improved pricing dynamics. Read More

Pharma: Other News To Note

• Watson Pharmaceuticals Inc., of Parsippany, N.J, said it will adopt Actavis as its new global name, effective in 2013. The firm acquired Actavis earlier this year. Read More

Financings Roundup

• Uluru Inc., of Addison, Texas, said company management will invest approximately $400,000 on similar terms to the investment of Melmed Holdings AG, of Zug, Switzerland, in September. That binding term sheet called for Melmed to make an equity investment of $2 million in Uluru at 40 cents per share for 5 million shares of common stock, plus warrants to purchase 3 million shares at 60 cents each for a term of one year. Read More

Clinic Roundup

• Hutchison MediPharma Ltd., of London, began a Phase I trial of theliatinib (HMPL-309) in advanced solid tumors. The objectives of the study are safety and tolerability, as well as determining the maximum tolerated dose. Efficacy against non-small-cell lung cancer and pharmacokinetics also will be evaluated. Theliatinib is an inhibitor of epidermal growth factor receptor (EGFR) that has shown strong antitumor activity against EGFR wild-type tumors in preclinical studies. Read More

Stock Movers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • Art concept for bladder

    Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

    BioWorld
    During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing